Latisse

What is Latisse?

• Latisse (Bimatoprost) is a prostaglandin analog, used to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness.

Error creating thumbnail:

Bimatoprost

Error creating thumbnail:

Structure of Bimatoprost

What are the uses of this medicine?

• Latisse (Bimatoprost) solution is a prescription treatment for hypotrichosis used to grow eyelashes, making them longer, thicker and darker.

How does this medicine work?

• Bimatoprost is a structural prostaglandin analog.
• Although the precise mechanism of action is unknown, the growth of eyelashes is believed to occur by increasing the percent of hairs in, and the duration of the anagen or growth phase.

Who Should Not Use this medicine ?

This medicine cannot be used in patients with:

• hypersensitivity to bimatoprost or to any of the ingredients.

What drug interactions can this medicine cause?

• No formal drug interaction studies have been conducted with Latisse.

Is this medicine FDA approved?

• Bimatoprost was approved for medical use in the United States in 2001.

How should this medicine be used?

Recommended dosage:

• The recommended dosage is one application nightly to the skin of the upper eyelid margin at the base of the eyelashes only.

Administration:

• Once nightly, start by ensuring your face is clean, makeup and contact lenses are removed.
• Remove an applicator from its tray.
• Then, holding the sterile applicator horizontally, place one drop of LATISSE® on the area of the applicator closest to the tip but not on the tip.
• Then immediately draw the applicator carefully across the skin of the upper eyelid margin at the base of the eyelashes (where the eyelashes meet the skin) going from the inner part of your lash line to the outer part.
• Blot any excess solution beyond the eyelid margin.
• Dispose of the applicator after one use.
• Repeat for the opposite upper eyelid margin using a new sterile applicator.
• This helps minimize any potential for contamination from one eyelid to another.
• DO NOT APPLY in your eye or to the lower lid.
• ONLY use the sterile applicators supplied with LATISSE® to apply the product.
• If you miss a dose, don’t try to “catch up.” Just apply LATISSE® solution the next evening.
• Fifty percent of patients treated with LATISSE® in a clinical study saw significant improvement by 2 months after starting treatment.
• If any LATISSE® solution gets into the eye proper, it is not expected to cause harm. The eye should not be rinsed.
• Don’t allow the tip of the bottle or applicator to contact surrounding structures, fingers, or any other unintended surface in order to avoid contamination by common bacteria known to cause infections.
• Contact lenses should be removed prior to application of LATISSE® and may be reinserted 15 minutes following its administration.
• Use of LATISSE® more than once a day will not increase the growth of eyelashes more than use once a day.

What are the dosage forms and brand names of this medicine?

This medicine is available in fallowing doasage form:

• As Ophthalmic solution containing bimatoprost 0.3 mg/mL.

This medicine is available in fallowing brand namesː

• LATISSE

What side effects can this medication cause?

The most common side effects of this medicine include:

• eye pruritus
• conjunctival hyperemia
• skin hyperpigmentation

What special precautions should I follow?

• Bimatoprost ophthalmic solution (LUMIGAN®) lowers intraocular pressure (IOP) when instilled directly to the eye in patients with elevated IOP. Concurrent administration of LATISSE® and intraocular pressure (IOP)-lowering prostaglandin analogs in ocular hypertensive patients may decrease the IOP-lowering effect. Patients using these products concomitantly should be closely monitored for changes to their IOP.
• Increased iris pigmentation has occurred when bimatoprost solution was administered. Iris pigmentation is likely to be permanent.
• Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes.
• There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with the skin surface. It is important to apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes using the accompanying sterile applicators, and to carefully blot any excess LATISSE® from the eyelid margin to avoid it running onto the cheek or other skin areas.
• LATISSE® solution should be used with caution in patients with active intraocular inflammation (e.g., uveitis) because the inflammation may be exacerbated.
• Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution (LUMIGAN®) for elevated IOP.
• The LATISSE® bottle must be kept intact during use. It is important to use LATISSE® solution as instructed, by placing one drop on the single-use-per-eye applicator. The bottle tip should not be allowed to contact any other surface since it could become contaminated. The accompanying sterile applicators should only be used on one eye and then discarded since reuse of applicators increases the potential for contamination and infections.
• LATISSE® contains benzalkonium chloride, which may be absorbed by and cause discoloration of soft contact lenses. Contact lenses should be removed prior to application of solution and may be reinserted 15 minutes following its administration.

What to do in case of emergency/overdose?

• In case of overdose, call the poison control helpline of your country. In the United States, call 1-800-222-1222.

• Overdose related information is also available online at poisonhelp.org/help.
• In the event that the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services. In the United States, call 911.

Can this medicine be used in pregnancy?

• There are no adequate and well-controlled studies of LATISSE® (bimatoprost ophthalmic solution) 0.03% administration in pregnant women.

Can this medicine be used in children?

• Use of LATISSE® was evaluated in pediatric patients who were post-chemotherapy or had alopecia areata, and adolescents who had hypotrichosis with no associated medical condition.

What are the active and inactive ingredients in this medicine?

• Active ingredient: bimatoprost
• Inactive ingredients: benzalkonium chloride; sodium chloride; sodium phosphate, dibasic; citric acid; and purified water. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH. The pH during its shelf life ranges from 6.8 - 7.8.

Who manufactures and distributes this medicine?

Distributed by:

• Allergan USA, Inc.
• Madison, NJ

What should I know about storage and disposal of this medication?

• Store LATISSE® solution at 36o to 77oF (2o to 25oC).

• Dailymed label info on Latisse
• FDA Latisse

Latisse Resources
Latest articles Most recent articles Ongoing trials	Wikipedia